SEC Filing Summary: NeoStem, Inc. (10-Q)
Business Context and Reporting Period
Company: NeoStem, Inc. (formerly Lisata Therapeutics, Inc.)
Reporting Period: Quarter and nine months ended September 30, 2010
Business Overview: NeoStem operates as a multi-dimensional international biopharmaceutical company with three primary business units: (i) U.S. adult stem cell collection and storage, (ii) China adult stem cell therapies and banking, and (iii) China pharmaceuticals (antibiotics) via its 51% ownership of Suzhou Erye Pharmaceuticals Company Ltd. ("Erye"). The company is also in the process of merging with Progenitor Cell Therapy, LLC ("PCT").
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2009 |
|---|---|---|---|
| Revenues | $16,475,558 | $51,716,260 | $157,709 |
| Gross Profit | $5,242,739 | $16,700,720 | $64,769 |
| Operating Loss | $(5,743,828) | $(11,855,049) | $(13,744,670) |
| Net Loss | $(5,994,638) | $(13,040,282) | $(13,777,820) |
| Net Loss Attributable to Common Shareholders | $(7,140,226) | $(17,279,494) | $(14,433,688) |
| Cash and Cash Equivalents (Sep 30, 2010) | $4,066,693 | ||
| Working Capital (Sep 30, 2010) | $7,687,725 | ||
| Notes Payable (Current) | $6,544,682 |
Note: Revenue growth is primarily driven by the inclusion of Erye's pharmaceutical sales, which were not present in the 2009 period.
Material Changes vs. Prior Period
- Revenue Surge: Revenues increased from $85,067 in Q3 2009 to $16.5 million in Q3 2010. This is almost entirely attributable to Erye's pharmaceutical product sales ($16.4 million), whereas 2009 revenues were derived solely from U.S. stem cell services.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased significantly to $9.3 million (Q3 2010) from $5.4 million (Q3 2009). This increase is due to the consolidation of Erye's operations, expansion of China-based stem cell initiatives, and increased professional fees related to the pending PCT merger.
- Capital Expenditures: Investing activities showed a significant outflow of $12.5 million for property and equipment, primarily for the construction of Erye's new manufacturing facility in China and the Beijing stem cell laboratory.
- Equity Transactions: The company raised approximately $13.1 million through the issuance of capital stock and $3.1 million from warrant exercises during the nine-month period. Series C Preferred Stock was converted to common stock in May 2010.
Guidance, Outlook, and Risks
- Outlook: Management expects to fund operations through existing cash, the 6% of net profits distributed from Erye, and potential additional capital raises. The company anticipates needing additional capital to fund the PCT merger and continued R&D.
- PCT Merger: NeoStem has agreed to merge with Progenitor Cell Therapy, LLC. The transaction involves issuing up to 11.2 million shares of common stock and warrants for up to 3 million shares, subject to conditions.
- Erye Expansion: Erye is relocating to a new facility expected to be fully operational in 2011, which will increase production capacity. Approximately 90% of 2009 sales capacity has been relocated.
- Risks:
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding insufficient U.S. GAAP qualified personnel at the Erye subsidiary and a lack of an internal audit system. Remediation is ongoing.
- Liquidity: The company has a history of operating losses and may face difficulty raising capital on acceptable terms.
- Legal Proceedings: Erye lost a patent infringement lawsuit regarding an antibiotic product (representing <2% of sales) and was enjoined from selling the product. A judgment of approximately $750,000 was accrued.
- China Operations: Risks include foreign exchange fluctuations, regulatory changes in the PRC, and restrictions on dividend repatriation.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of Erye's pharmaceutical sales, which now constitute the vast majority of total revenue, compared to the legacy U.S. stem cell business.
- Internal Control Remediation: Monitor the progress of remediation plans for the material weaknesses in internal controls, particularly regarding U.S. GAAP compliance at the China subsidiary.
- Cash Burn vs. Capital Needs: Assess the sufficiency of the $4.1 million cash balance against the $12.5 million capital expenditure outflow and ongoing operating losses.
- PCT Merger Dilution: Evaluate the potential dilution impact of the proposed issuance of 11.2 million shares and warrants associated with the PCT merger.
- Legal Exposure: Confirm the status of the patent infringement appeal and any potential impact on Erye's broader product portfolio beyond the specific enjoined product.